Wouter Vervecken
Vorstandsvorsitzender bei Oxyrane UK Ltd.
Aktive Positionen von Wouter Vervecken
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Oxyrane UK Ltd.
 Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Vorstandsvorsitzender | - | - |
| Technik-/Wissenschafts-/F&E-Leiter | 01.01.2008 | - |
Karriereverlauf von Wouter Vervecken
Ausbildung von Wouter Vervecken
| Ghent University | Doctorate Degree |
Statistik
International
| Vereinigtes Königreich | 2 |
| Belgien | 2 |
Operativ
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Oxyrane UK Ltd.
Oxyrane UK Ltd. Pharmaceuticals: MajorHealth Technology Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom. | Health Technology |
- Börse
- Insiders
- Wouter Vervecken
- Erfahrung
